In contrast, the treatment with the GPER agonist G-1 in preclinical studies has consistent antitumor activities in several cancers, including cutaneous melanoma (9), breast (24), ovarian (20, 35), pancreatic (17), and glioma (19). This evidence concerns the gene GPER1 and glioma.